Get the Stockscreener App
1.68
3.07%
0.05
Entera Bio Ltd stock is traded at $1.68, with a volume of 19,817.
It is up +3.07% in the last 24 hours and down -9.19% over the past month.
See More
Previous Close:
$1.63
Open:
$1.655
24h Volume:
19,817
Relative Volume:
0.18
Market Cap:
$60.04M
Revenue:
$134.00K
Net Income/Loss:
$-9.93M
P/E Ratio:
-4.9412
EPS:
-0.34
Net Cash Flow:
$-6.72M
1W Performance:
-7.44%
1M Performance:
-9.19%
6M Performance:
-9.19%
1Y Performance:
-9.68%
1-Day Range:
$1.655
$1.75
1-Week Range:
$1.62
$1.83
52-Week Range:
$1.41
$3.35
Entera Bio Ltd Stock (ENTX) Company Profile
Name
Entera Bio Ltd
Sector
Industry
Phone
972-2-532-7151
Address
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.68 | 60.04M | 134.00K | -9.93M | -6.72M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-21 | Initiated | Aegis Capital | Buy |
Entera Bio Ltd Stock (ENTX) Latest News
Entera Bio Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Entera Bio (NASDAQ:ENTX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Entera Bio Reports Transformative Year in 2024 - TipRanks
Entera Bio Ltd. (ENTX) reports earnings - Quartz
Entera Bio Announces 2024 Financial Results and Updates - TipRanks
Entera Bio's Breakthrough: Oral Peptide Programs Show Promise as 2024 Results Reveal $21M War Chest - Stock Titan
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
Entera Bio Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Entera Bio’s (ENTX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Opko Health, Entera Bio sign agreement for oral GLP-1/glucagon dual agonist peptide - BioWorld MedTech
OPKO and Entera team up on oral obesity candidate - The Pharma Letter
OPKO and Entera Bio partner on oral obesity treatment By Investing.com - Investing.com Australia
OPKO And Entera Bio Team Up For Game-Changing Obesity Pill - Finimize
OPKO and Entera partner to develop obesity pill -March 17, 2025 at 08:54 am EDT - Marketscreener.com
Entera Bio Collaborates with OPKO for Oral GLP-1/Glucagon - TipRanks
OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity -March 17, 2025 at 08:38 am EDT - Marketscreener.com
OPKO and Entera Bio partner on oral obesity treatment - Investing.com India
OPKO Health and Entera Bio Enter into Collaboration - GlobeNewswire
Revolutionary Oral GLP-1 Obesity Treatment: OPKO and Entera Join Forces to Challenge Injectable Market - StockTitan
Entera Bio (ENTX) Expected to Announce Quarterly Earnings on Friday - Defense World
Entera Bio Ltd. to Host Earnings Call - ACCESS Newswire
Entera Bio to Participate in Upcoming Events - GlobeNewswire
Can Entera Bio's Upcoming Scientific Data Reshape Oral Peptide Therapy? Major Conference Schedule Revealed - Stock Titan
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskel - The Manila Times
Could This Oral Osteoporosis Treatment Replace Daily Injections? Phase 2 Data Reveals Promising Results - StockTitan
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 31.6% in January - MarketBeat
US Penny Stocks: 3 Picks With Market Caps Over $60M - Yahoo Finance
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Increase in Short Interest - MarketBeat
145,843 Shares in Entera Bio Ltd. (NASDAQ:ENTX) Acquired by Perigon Wealth Management LLC - MarketBeat
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 23.1% in January - MarketBeat
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Entera Bio CEO to Present Business Updates at Oppenheimer Healthcare Conference - StockTitan
Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Decrease in Short Interest - Defense World
Entera Bio files Exhibit 5.1 with SEC By Investing.com - Investing.com South Africa
Entera Bio files Exhibit 5.1 with SEC - Investing.com
Entera Bio (NASDAQ:ENTX) Stock Price Up 1.1% – Still a Buy? - Defense World
Entera Bio (NASDAQ:ENTX) Shares Up 1.1%Time to Buy? - MarketBeat
Hypoparathyroidism Market Overview, Trends, Insights, - openPR
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate - Simply Wall St
Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Rises By 19.0% - MarketBeat
Knoll Capital Management, LLC's Strategic Acquisition in Entera Bio Ltd - GuruFocus.com
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update - MarketBeat
Entera Bio Ltd Stock (ENTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):